May 26, 2020
Emgality® Shows Improvement in Work Productivity and Health and Well-Being Between Attacks in Patients with Migraine and a History of Preventive Treatment Failure
Apr 29, 2020
Teva Canada announces the launch of AJOVY(TM) for the preventive treatment of migraine in adults who have at least four migraine days per month
Apr 02, 2020
COVID-19 Pandemic in the US May Curtail Uptake of Recent Acute Migraine Market Entrants, Diminishing Specialists' Prelaunch Expectations that Biohaven's Nurtec ODT Would Challenge Allergan's Ubrelvy and Eli Lilly's Reyvow
Dec 18, 2019
Amgen/Novartis' Aimovig Label Revision and Teva's Ajovy Autoinjector Delay Clear the Way for Continued Growth of Eli Lilly's Emgality in the US Migraine Prevention Market, According to Spherix Global Insights
Oct 17, 2019
Prime Therapeutics Study Finds Use, Costs for New Migraine Prevention Medications Projected to Triple by 2020
Oct 02, 2019
EMGALITY(TM) (galcanezumab) now available in Canada for preventive treatment of migraine
Sep 26, 2019
Strong Uptake in the Expanding Preventive-Treated Episodic Migraine Segment Has Propelled Eli Lilly's Third-to-Market Emgality to Second Place in the Anti-CGRP Class Surpassing Teva's Ajovy
Sep 11, 2019
Unimpeded by Allergan's Botox Dominance, Amgen/Novartis' Aimovig, Teva's Ajovy, and Eli Lilly's Emgality Use at the Patient Level is More Robust Within the Episodic Migraine Segment Than Physicians Are Aware of
Jun 25, 2019
Global Leaders in Migraine Research to Convene at The American Headache Society 61st Annual Scientific Meeting
Jun 04, 2019
FDA Approves Emgality® (galcanezumab-gnlm) as the First and Only Medication for the Treatment of Episodic Cluster Headache that Reduces the Frequency of Attacks
Mar 25, 2019
Spherix Global Insights' Quarterly Update on the US Migraine Prevention Market Reveals Best-In-Class Sales and Medical Affairs Support as the Driving Force Behind Teva's Ajovy Early Launch Success
Dec 18, 2018
Global Medical Device Market Anticipated to Surpass $400 Billion by 2023
Dec 04, 2018
Migraine Drugs Market Size Worth $7.8 Billion by 2025 | CAGR: 18.0%: Grand View Research, Inc.
Jun 27, 2018
AHS 2018: Lilly Highlights Positive Phase 3 Results from the Largest Controlled Preventive Trial in Episodic Cluster Headache
Nov 20, 2017
PharmaPoint: Migraine - Global Drug Forecast and Market Analysis to 2026
Oct 18, 2017
Clinical Trials and Advanced Development of Innovative Drug Treatments Boosting Biotech Sector Gains